A carregar...
Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment
AIM: Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this stud...
Na minha lista:
| Publicado no: | CNS Neurosci Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698982/ https://ncbi.nlm.nih.gov/pubmed/31066225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13142 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|